The European Committee for Medicinal Products (CHMP) rejects Prestige Biopharma’s biosimilar referencing Herceptin; Prime Therapeutics’ plan to leverage biosimilars resulted in savings for patients; Samsung Biologics and AstraZeneca liquidated their joint venture (Archigen Biotech).
Prestige’s Trastuzumab Get Thumbs Down From CHMP
According to the European Medicine Agency’s European Committee for Medicinal Products (CHMP), Prestige Biopharma’s trastuzumab biosimilar (Tuznue; Hervelous) referencing Herceptin has not been recommended for approval.
Trastuzumab products are used to treat human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancers. The biosimilar was to be marketed as Hervelous in Belgium and Tuznue in the other European Union member nations.
The committee claimed that the manufacturing process of Tuznue used during clinical testing differed from the process required for commercial production. The CHMP concluded that the difference suggested that the studies did not provide enough evidence to show that the biosimilar candidate would be bioequivalent to the reference product.
The news comes after Prestige Biopharma announced positive phase 3 results of Tuznue’s use in patients with erb-B2 receptor tyrosine kinase 2-positive breast cancer in March 2022. Prestige’s manufacturing facility for Tuznue was also granted European Union Good Manufacturing Practices certification in February 2022.
Prestige Biopharma will be able to ask for re-examination of the recommendation refusal within 15 days of receiving the opinion.
Prime Therapeutics Sees Savings With Biosimilars
Prime Therapeutics said that its MedDrive program, its medical drug management program that leveraged biosimilars as a solution to patients’ high drug costs, cut expenses for its members by 26% in a single year.
The program launched in May 2021 and applied to Prime Therapeutics beneficiaries enrolled in 1 of its 23 Blue Plans. MedDrive helps patients reap the savings benefits from improving Prime’s contracts with manufacturers and recommending lower-cost alternatives to expensive brand-name specialty drugs, including biosimilars and generics. The program recommends biosimilars in 3 specialty drug categories, primarily for oncology.
“Drug prices continue to rise, which puts pressure both on insurers and the members they serve… MedDrive leverages the collective strengths of Blue Plans and Prime to put the brakes on medical drug spend without compromising patient care,” said Kelly McGrail-Pokuta, vice president of trade relations and strategy and chief trade relations officer at Prime Therapeutics.
The MedDrive program also utilizes advanced analytics and proactive consulting to clarify what factors are drivers for medical drug spending and predict changes that can lead to savings.
Samsung Biologics and AstraZeneca End Joint Venture
Samsung Biologics and AstraZeneca announced the end of their joint venture Archigen Biotech. The companies cited the development suspension of SAIT101, a rituximab biosimilar.
The move comes 2 months after Samsung Biologics’ board authorized the liquidation of Archigen Biotech, which was established in 2014. SAIT101 would have referenced Rituxan and would’ve been used to treat patients with certain types of lymphoma.
Samsung Biologics and AstraZeneca made the decision to halt SAIT101 production in the second half of 2020 after competitors, including Celltrion Healthcare, starting selling their own rituximab biosimilars.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.